NEUROCRINE BIOSCIENCES INC - 10-Q Filing
Neurocrine Biosciences reports Q3 2026 financial results including revenue from INGREZZA, CRENESSITY, and VYKATXR product lines.
Tickers: $NBIX
Read the full article at SEC EDGAR
Part of the story Manulife Reports Record Core Earnings and Strong Asian Growth in Q3 2026 (106 articles)